Development of Nanoscale Oil Bodies for Targeted Treatment of Lung Cancer

Lung cancer is the most widespread disease and is frequently associated with a high level of epidermal growth factor receptor (EGFR). This study was thus conducted to provide a proof-of-concept approach for targeted therapy of lung cancer by development of nanoscale oil bodies (NOBs). This was carri...

Full description

Saved in:
Bibliographic Details
Published inJournal of agricultural and food chemistry Vol. 66; no. 36; pp. 9438 - 9445
Main Authors Chiang, Chung-Jen, Lin, Li-Jen, Wu, Chia-Pei, Chen, Chih-Jung, Chao, Yun-Peng
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 12.09.2018
Subjects
Animals
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - chemistry
Camptothecin - administration & dosage
Camptothecin - chemistry
Drug Compounding
Female
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Mice
Mice, Inbred BALB C
Molecular Targeted Therapy
Nanostructures - administration & dosage
Nanostructures - chemistry
Plant Oils - chemistry
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Receptor, Epidermal Growth Factor - metabolism
lung cancer
nanoscale oil bodies
camptothecin
epidermal growth factor receptor
Online AccessGet full text

Cover

More Information
Summary:Lung cancer is the most widespread disease and is frequently associated with a high level of epidermal growth factor receptor (EGFR). This study was thus conducted to provide a proof-of-concept approach for targeted therapy of lung cancer by development of nanoscale oil bodies (NOBs). This was carried out by fusion of anti-EGFR affibody (ZEGFR2) with oleosin (Ole), a structure protein of plant seed oils. The fusion protein (Ole-ZEGFR2) was produced in Escherichia coli. NOBs were spontaneously assembled from plant oil, phospholipids, and Ole-ZEGFR2. Consequently, Ole-ZEGFR2-based NOBs were selectively internalized by EGFR-positive lung cancer cells with an efficiency exceeding 90%. Furthermore, the hydrophobic anticancer drug, camptothecin (CPT), was encapsulated into Ole-ZEGFR2-based NOBs. The administration of the CPT formulation based on NOBs resulted in a strong antitumor activity both in vitro and in vivo.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-8561
1520-5118
DOI:10.1021/acs.jafc.8b02972